Medicare Enrolled
Dr. Christopher Haberman, M.D.
Hematology & Oncology · Panama City, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Haberman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Haberman? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Haberman
Dr. Christopher Haberman is a hematology & oncology in Panama City, FL, with 18 years in practice. Based on federal Medicare data, Dr. Haberman performed 162,977 Medicare services across 4,300 unique beneficiaries.
Between the years covered by Open Payments, Dr. Haberman received a total of $19,059 from 100 pharmaceutical and/or device companies across 1091 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Haberman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 3% volume in FL$ $19,059 industry payments
Medicare Practice Summary
Medicare Utilization ↗162,977
Medicare services
Top 3% in FL for hematology & oncology
4,300
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,054 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 60,750 | $1 | $5 |
| Nivolumab injection (Opdivo) | 15,400 | $24 | $82 |
| Anti-nausea injection (fosaprepitant) | 14,550 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 12,540 | $18 | $70 |
| Daratumumab injection (Darzalex) | 11,520 | $38 | $136 |
| Pembrolizumab injection (Keytruda) | 10,400 | $44 | $148 |
| Epoetin alfa injection (Procrit) for anemia | 6,540 | $6 | $55 |
| Contrast dye for imaging (iodine-based) | 5,700 | $0 | $3 |
| Paclitaxel chemotherapy injection | 4,470 | $0 | $1 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 3,180 | $22 | $166 |
| Complete blood count (CBC) with differential | 2,297 | $8 | $35 |
| Dexamethasone injection (steroid) | 1,939 | $0 | $1 |
| Blood draw (venipuncture) | 1,914 | $8 | $19 |
| Injection, granisetron hydrochloride, 100 mcg | 1,520 | $0 | $25 |
| Comprehensive metabolic blood panel | 1,449 | $10 | $62 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,340 | $1 | $122 |
| Office visit, established patient (30-39 min) | 945 | $92 | $224 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 528 | $85 | $1,444 |
| Injection of additional new drug or substance into vein | 519 | $12 | $105 |
| Administration of chemotherapy into vein, 1 hour or less | 479 | $99 | $686 |
| Injection, carboplatin, 50 mg | 475 | $2 | $300 |
| Antibody identification test, platelet associated immunoglobulin assay | 423 | $12 | $155 |
| Drug injection, under skin or into muscle | 423 | $11 | $93 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 319 | $55 | $205 |
| Injection, fluorouracil, 500 mg | 318 | $2 | $14 |
| Ferritin level test (iron stores) | 301 | $13 | $58 |
| Iron level test | 301 | $6 | $26 |
| Iron binding capacity test | 301 | $9 | $34 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 217 | $21 | $152 |
| Office visit, established patient (20-29 min) | 175 | $66 | $148 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 142 | $47 | $304 |
| Administration of additional new drug or substance into vein, 1 hour or less | 137 | $50 | $334 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 130 | $25 | $141 |
| New patient office visit, complex (60-74 min) | 107 | $168 | $432 |
| Injection, diphenhydramine hcl, up to 50 mg | 104 | $1 | $7 |
| Office visit, established patient, complex (40-54 min) | 88 | $122 | $301 |
| Magnesium level test | 87 | $7 | $28 |
| Administration of chemotherapy into vein, each additional hour | 85 | $22 | $156 |
| Irrigation of implanted venous access drug delivery device | 78 | $17 | $111 |
| Hospital follow-up visit, high complexity | 76 | $96 | $232 |
| Lactate dehydrogenase (enzyme) level | 75 | $6 | $30 |
| New patient office visit (45-59 min) | 67 | $125 | $343 |
| Urinalysis, manual | 63 | $3 | $15 |
| Infusion, normal saline solution , 1000 cc | 61 | $2 | $19 |
| Unclassified drugs | 47 | $1 | $9 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 46 | $1 | $19 |
| Ct scan of chest with contrast | 44 | $79 | $1,005 |
| CT scan of abdomen and pelvis with contrast | 44 | $218 | $1,400 |
| Infusion into a vein for hydration, each additional hour | 40 | $10 | $73 |
| Application of on-body injector for under skin injection | 40 | $14 | $96 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 38 | $132 | $986 |
| Initial hospital admission, high complexity | 35 | $140 | $412 |
| Infusion into a vein for hydration, 31-60 minutes | 28 | $25 | $249 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 24 | $1 | $19 |
| CT scan of chest, without contrast | 16 | $92 | $861 |
| Injection of drug or substance into vein | 16 | $29 | $240 |
| Haptoglobin (serum protein) level | 15 | $12 | $64 |
| Blood creatinine level | 11 | $5 | $30 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
37.6% high complexity
56.9% medium
5.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$19,059
Total received (2018-2024)
Avg $2,723/year across 7 years
Top 26% in FL for hematology & oncology
100
Companies
1,091
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$18,874 (99.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$185 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,438
2023$3,036
2022$2,898
2021$2,745
2020$1,527
2019$2,707
2018$2,707
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,959
AstraZeneca Pharmaceuticals LP
$1,150
Janssen Biotech, Inc.
$1,040
Celgene Corporation
$1,004
Amgen Inc.
$986
E.R. Squibb & Sons, L.L.C.
$911
Regeneron Healthcare Solutions, Inc.
$877
Merck Sharp & Dohme Corporation
$749
Genentech USA, Inc.
$556
Daiichi Sankyo Inc.
$554
GENZYME CORPORATION
$477
Astellas Pharma US Inc
$421
Lilly USA, LLC
$401
Ipsen Biopharmaceuticals, Inc
$393
Eisai Inc.
$384
Merck Sharp & Dohme LLC
$360
Pharmacyclics LLC, An AbbVie Company
$331
BeiGene USA, Inc.
$314
Incyte Corporation
$307
GlaxoSmithKline, LLC.
$286
PFIZER INC.
$278
Bayer HealthCare Pharmaceuticals Inc.
$198
EISAI INC.
$196
Takeda Pharmaceuticals U.S.A., Inc.
$194
Octapharma USA, Inc.
$185
Pharmacosmos Therapeutics Inc.
$176
AbbVie, Inc.
$164
Taiho Oncology, Inc.
$157
EMD Serono, Inc.
$150
Coherus Biosciences Inc.
$148
ABBVIE INC.
$141
ARRAY BIOPHARMA INC
$130
Puma Biotechnology, Inc.
$124
Seagen Inc.
$123
Karyopharm Therapeutics Inc.
$120
Mirati Therapeutics, Inc.
$117
Seattle Genetics, Inc.
$110
Kyowa Kirin, Inc.
$107
Blueprint Medicines Corporation
$102
Stemline Therapeutics Inc.
$101
Exelixis Inc.
$101
JAZZ PHARMACEUTICALS INC.
$98
Boehringer Ingelheim Pharmaceuticals, Inc.
$97
TerSera Therapeutics LLC
$96
Jazz Pharmaceuticals Inc.
$91
SOBI, INC
$80
G1 Therapeutics, Inc.
$75
Bayer Healthcare Pharmaceuticals Inc.
$72
AVEO Pharmaceuticals, Inc.
$71
CSL Behring
$71
Global Blood Therapeutics, Inc.
$66
Deciphera Pharmaceuticals Inc.
$65
Apellis Pharmaceuticals, Inc.
$63
TESARO, Inc.
$59
Clovis Oncology, Inc.
$59
Pharmacyclics LLC, an AbbVie Company
$56
MEDIVATION FIELD SOLUTIONS LLC
$56
Epizyme, Inc.,
$55
SpringWorks Therapeutics, Inc.
$53
MorphoSys, US Inc.
$51
Rigel Pharmaceuticals, Inc.
$51
ADC Therapeutics America, Inc.
$49
Dova Pharmaceuticals
$47
Gilead Sciences, Inc.
$47
Teva Pharmaceuticals USA, Inc.
$47
SANOFI-AVENTIS U.S. LLC
$45
PUMA BIOTECHNOLOGY, INC.
$41
Foundation Medicine, Inc.
$40
Myriad Genetic Laboratories, Inc.
$39
AbbVie Inc.
$39
Progenics Pharmaceuticals, Inc.
$37
Agios Pharmaceuticals, Inc.
$36
Aveo Pharmaceuticals, Inc.
$36
Alexion Pharmaceuticals, Inc.
$34
Array BioPharma Inc.
$32
Acceleron Pharma, Inc.
$32
Janssen Pharmaceuticals, Inc
$31
Aurobindo Pharma USA, Inc.
$31
EUSA Pharma (US) LLC
$29
Shire North American Group Inc
$28
Novocure Inc.
$28
Heron Therapeutics, Inc.
$27
Helsinn Therapeutics (U.S.), Inc.
$27
PharmaEssentia USA Corporation
$27
Adaptive Biotechnologies Corporation
$26
AMAG Pharmaceuticals, Inc.
$25
Emmaus Medical, Inc.
$23
PROGENICS PHARMACEUTICALS, INC.
$18
Genmab U.S., Inc.
$18
ImmunoGen, Inc.
$18
TG Therapeutics, Inc.
$17
Acrotech Biopharma Inc.
$16
SERVIER PHARMACEUTICALS LLC
$15
Alnylam Pharmaceuticals Inc.
$15
Immunocore Limited
$15
Sumitomo Pharma America, Inc.
$14
Servier Pharmaceuticals LLC
$13
Verastem, Inc.
$11
Kite Pharma, Inc.
$11
Sirtex Medical Inc
$7
Top 3 companies account for 21.8% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · AYVAKIT · Abraxane · Afstyla · Alecensa · Aliqopa · Avastin · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRACAnalysis · BRAFTOVI · BRUKINSA · Bavencio · Beleodaq · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · CINVANTI · COSELA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Empaveli · Endari · Enhertu · Epkinly · Erleada · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE CDX · FRUZAQLA · Fabhalta · GAVRETO · GAZYVA · GILOTRIF · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Idelvion · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · MYRISK · Monoferric · Morphabond ER · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Oncology · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PYLARIFY · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · Prolia · QINLOCK · Quzyttir · REBLOZYL · RYBREVANT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · Somatuline Depot · Stivarga · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPMETKO · TIBSOVO · TIVDAK · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tecentriq · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · VALCHLOR · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · VYXEOS · Venclexta · Vitrakvi · Vyloy · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $12 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
6
Per 100K population
3.3
County median income
$70,188
Nearest hospital
HCA FLORIDA GULF COAST HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Haberman is a mixed practice specialist, with above-average Medicare volume (top 3% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Haberman experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Haberman performed 60,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Haberman receive payments from pharmaceutical companies?
Yes. Dr. Haberman received a total of $19,059 from 100 companies across 1,091 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Haberman's costs compare to other hematology & oncologys in Panama City?
Dr. Haberman's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Haberman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Panama City
Browse hematology & oncologys in Panama City ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology